Paper34857016
Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
Alors-Perez E and 25 others. J Exp Clin Cancer Res, 2021. Cited by 40 papers, by iCite.
Cite this record
ConductScience Library. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. Papers, record 34857016. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34857016
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma | Major topic |
| Carcinoma, Pancreatic Ductal | Major topic |
| Neoplastic Stem Cells | Major topic |
| Phosphoproteins | Major topic |
| RNA Splicing Factors | Major topic |
| Adult | |
| Aged | |
| Animals | |
| Disease Models, Animal | |
| Female | |
| Humans | |
| Male | |
| Mice | |
| Middle Aged | |
| Zebrafish |
Source PubMed
Grants18
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| BFU2016-80360-R | Ministerio de Economía y Competitividad | PubMed | ||
| PID2019-105201RB-I00 | Ministerio de Ciencia, Innovación y Universidades | PubMed | ||
| PID2019-105564RB-I00 | Ministerio de Ciencia, Innovación y Universidades | PubMed | ||
| FPU14/04290 | Ministerio de Ciencia, Innovación y Universidades | PubMed | ||
| FPU18/02275 | Ministerio de Ciencia, Innovación y Universidades | PubMed | ||
| FPU16/06190 | Ministerio de Ciencia, Innovación y Universidades | PubMed | ||
| PI17/02287 | Instituto de Salud Carlos III | PubMed | ||
| PI20/01301 | Instituto de Salud Carlos III | PubMed | ||
| PI18/00757 | Instituto de Salud Carlos III | PubMed | ||
| DTS20/00050 | Instituto de Salud Carlos III | PubMed | ||
| CD19/00255 | Instituto de Salud Carlos III | PubMed | ||
| FI17/00282 | Instituto de Salud Carlos III | PubMed | ||
| GC16173694BARB | Fundación Científica Asociación Española Contra el Cáncer | PubMed | ||
| GETNE2016 | GETNE | PubMed | ||
| GETNE2019 Research Grant | GETNE | PubMed | ||
| AIRC 5x1000 n. 12182 | Fondazione Italiana per la Ricerca sul Cancro | PubMed | ||
| FIMPCUP_J38D19000690001 | Ministero della Salute | PubMed | ||
| 203885/2017 | Fondazione Cariverona: Oncology Biobank Project "Antonio Schiavi" | PubMed |
Source PubMed
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32683683 | Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. | CA Cancer J Clin | 2020 | https://conductscience.org/library/papers/32683683 | PubMed |
| 2 | 29717230 | Therapeutic developments in pancreatic cancer: current and future perspectives. | Nat Rev Gastroenterol Hepatol | 2018 | https://conductscience.org/library/papers/29717230 | PubMed |
| 3 | 27158978 | Pancreatic cancer. | Nat Rev Dis Primers | 2016 | https://conductscience.org/library/papers/27158978 | PubMed |
| 4 | 26909576 | Genomic analyses identify molecular subtypes of pancreatic cancer. | Nature | 2016 | https://conductscience.org/library/papers/26909576 | PubMed |
| 5 | 32434734 | RNA Splicing and Cancer. | Trends Cancer | 2020 | https://conductscience.org/library/papers/32434734 | PubMed |
| 6 | 31611195 | Altered RNA Processing in Cancer Pathogenesis and Therapy. | Cancer Discov | 2019 | https://conductscience.org/library/papers/31611195 | PubMed |
| 7 | 32303702 | Roles and mechanisms of alternative splicing in cancer - implications for care. | Nat Rev Clin Oncol | 2020 | https://conductscience.org/library/papers/32303702 | PubMed |
| 8 | 21178653 | Characterization of alternative spliceoforms and the RNA splicing machinery in pancreatic cancer. | Pancreas | 2011 | https://conductscience.org/library/papers/21178653 | PubMed |
| 9 | 31483163 | Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data. | DNA Cell Biol | 2019 | https://conductscience.org/library/papers/31483163 | PubMed |
| 10 | 32559497 | Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. | Cancer Cell | 2020 | https://conductscience.org/library/papers/32559497 | PubMed |
| 11 | 31275849 | Genome-Wide Profiling Reveals the Landscape of Prognostic Alternative Splicing Signatures in Pancreatic Ductal Adenocarcinoma. | Front Oncol | 2019 | https://conductscience.org/library/papers/31275849 | PubMed |
| 12 | 32905346 | The biological function and clinical significance of SF3B1 mutations in cancer. | Biomark Res | 2020 | https://conductscience.org/library/papers/32905346 | PubMed |
| 13 | 27282250 | RNA splicing factors as oncoproteins and tumour suppressors. | Nat Rev Cancer | 2016 | https://conductscience.org/library/papers/27282250 | PubMed |
| 14 | 31344348 | Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. | Transl Res | 2019 | https://conductscience.org/library/papers/31344348 | PubMed |
| 15 | 33038489 | Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma. | Cancer Lett | 2021 | https://conductscience.org/library/papers/33038489 | PubMed |
| 16 | 30130664 | Pancreatic cancer stem cells: A state or an entity? | Semin Cancer Biol | 2018 | https://conductscience.org/library/papers/30130664 | PubMed |
| 17 | 19260470 | Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. | Hepatogastroenterology | 2008 | https://conductscience.org/library/papers/19260470 | PubMed |
| 18 | 25262208 | Intracellular autofluorescence: a biomarker for epithelial cancer stem cells. | Nat Methods | 2014 | https://conductscience.org/library/papers/25262208 | PubMed |
| 19 | 27578530 | Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. | Gastroenterology | 2016 | https://conductscience.org/library/papers/27578530 | PubMed |
| 20 | 27282075 | RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. | Mol Oncol | 2016 | https://conductscience.org/library/papers/27282075 | PubMed |
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42870295 | U2 snRNP inhibition hampers pancreatic cancer cell viability by disrupting DNA repair proficiency and mitotic checkpoint integrity. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42870295 | PubMed |
| 42649859 | The Role of Splicing Machinery as a Promising Potential Therapeutic Target for Pituitary Neuroendocrine Tumors (PitNETs). | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42649859 | PubMed |
| 41986348 | Spliceosome induction is a druggable dependency of RAS-driven senescence and cancer. | Nat Commun | 2026 | https://conductscience.org/library/papers/41986348 | PubMed |
| 41976280 | p53 Isoforms as Modifiers of the p53-Dependent Responses: A Hidden Code? | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41976280 | PubMed |
| 41228342 | Molecular Pathology of Pancreatic Ductal Adenocarcinoma. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228342 | PubMed |
| 41179739 | Dysregulation of mRNA splicing in urothelial carcinoma: Clinical, diagnostic and therapeutic implications. | Bladder Cancer | 2025 | https://conductscience.org/library/papers/41179739 | PubMed |
| 40702779 | Systematic characterization of full-length RNA isoforms in human colorectal cancer at single-cell resolution. | Protein Cell | 2025 | https://conductscience.org/library/papers/40702779 | PubMed |
| 40581690 | Impaired splicing machinery in craniopharyngiomas unveils PRPF8 and RAVER1 as novel biomarkers and therapeutic targets. | Acta Neuropathol Commun | 2025 | https://conductscience.org/library/papers/40581690 | PubMed |
| 40563429 | Alternative Splicing in Tumorigenesis and Cancer Therapy. | Biomolecules | 2025 | https://conductscience.org/library/papers/40563429 | PubMed |
| 40301643 | Exploring RNA biology in pseudomyxoma peritonei uncovers splicing dysregulation as a novel, targetable molecular vulnerability. | Cancer Gene Ther | 2025 | https://conductscience.org/library/papers/40301643 | PubMed |
| 39885614 | Targeting RNA splicing modulation: new perspectives for anticancer strategy? | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/39885614 | PubMed |
| 39725737 | The splicing machinery is dysregulated and represents a therapeutic vulnerability in breast cancer. | Cell Mol Life Sci | 2024 | https://conductscience.org/library/papers/39725737 | PubMed |
| 39232176 | The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. | Cancer Gene Ther | 2024 | https://conductscience.org/library/papers/39232176 | PubMed |
| 39138145 | Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39138145 | PubMed |
| 39000035 | Splicing Machinery Is Impaired in Oral Squamous Cell Carcinomas and Linked to Key Pathophysiological Features. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39000035 | PubMed |
| 38904016 | Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target. | Int J Biol Sci | 2024 | https://conductscience.org/library/papers/38904016 | PubMed |
| 38790138 | Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets. | Mol Oncol | 2024 | https://conductscience.org/library/papers/38790138 | PubMed |
| 38658776 | Alternative splicing in prostate cancer progression and therapeutic resistance. | Oncogene | 2024 | https://conductscience.org/library/papers/38658776 | PubMed |
| 38325381 | An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. | Cell Rep Med | 2024 | https://conductscience.org/library/papers/38325381 | PubMed |
| 38187140 | Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus response. | Mol Ther Nucleic Acids | 2024 | https://conductscience.org/library/papers/38187140 | PubMed |
Genes36
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34857016
GET https://conductscience.org/api/papers/v1/34857016/authors?page=2